Last reviewed · How we verify
moxifloxacin/prednisolone combination
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while prednisolone is a corticosteroid that reduces inflammation by inhibiting phospholipase A2 and other enzymes.
Moxifloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase and topoisomerase IV, while prednisolone is a corticosteroid that reduces inflammation by inhibiting phospholipase A2 and other enzymes. Used for Bacterial conjunctivitis, Uveitis.
At a glance
| Generic name | moxifloxacin/prednisolone combination |
|---|---|
| Also known as | moxifloxacin 0,5%; predfort |
| Sponsor | Adapt Produtos Oftalmológicos Ltda. |
| Drug class | Fluoroquinolone antibiotic and corticosteroid combination |
| Target | DNA gyrase and topoisomerase IV (moxifloxacin), phospholipase A2 and other enzymes (prednisolone) |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Moxifloxacin works by binding to the bacterial enzymes DNA gyrase and topoisomerase IV, preventing bacterial DNA replication and transcription. Prednisolone, on the other hand, reduces inflammation by inhibiting the production of pro-inflammatory mediators such as prostaglandins and leukotrienes. This combination of mechanisms makes moxifloxacin/prednisolone effective against bacterial infections and inflammation.
Approved indications
- Bacterial conjunctivitis
- Uveitis
Common side effects
- Increased intraocular pressure
- Cataract
- Glaucoma
Key clinical trials
- Study of Complication Rates in Cataract Surgery Patients Treated With Combined Pre-operative NSAID, OMIDRIA, and Subconjunctival Triamcinolone Acetonide Compared With Peri-operative SOC (PHASE1, PHASE2)
- Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis (PHASE3)
- Efficacy of Moxifloxacin/Prednisolone in Prevention of Post Surgery Inflammation (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: